POSSIBILITIES OF CORRECTION OF HYPERAMMONEMIA IN THE PATIENTS WITH TYPE 2 DIABETES MELLITUS

Authors

DOI:

https://doi.org/10.21856/j-PEP.2022.1.15

Keywords:

type 2 diabetes mellitus, hyperammonemia, cognitive functions, alpha-lipoic acid

Abstract

The article presents data on the incidence of complications such as cognitive impairment, cardiac autonomic neuropathy, diabetic peripheral neuropathy, as well as the presence of steatosis and liver fibrosis at normal transaminases in patients with type 2 diabetes mellitus with hyperammonemia and the impact of alpha-lipoic acid on the level of ammonia. The aim of the study was to examine the incidence of neurological complications in patients with type 2 diabetes mellitus and hyperammonemia and the effect of alpha-lipoic acid on ammonia level.

Materials and methods. 30 middle-age (53.95±2.43 yrs) type 2 diabetic patients (M/F: 9/21) with hyperammonemia (77.67±11.5 micromol/L) were observed. The diabetes duration was 9.81±1.59 yrs, BMI - 33.26±1.16 kg/m2, the average level of glycated hemoglobin was 7.95±0.33 %. All patients were prescribed in addition to their antidiabetic therapy iv infusion of alpha-lipoic acid (Dialipon turbo 50.0 ml) for 10 days.

Results. The positive relationship between ammonia levels and the HOMA-IR index has been found. After the treatment, there was a probable decrease in ammonia levels from baseline by 67.78%, and improvement in cognitive function according to the MOSA scale.

Conclusions. Insulin resistance is a negative risk factor for hyperammonemia in patients with type 2 diabetes mellitus. Alpha-lipoic acid significantly reduces the levels of neurotoxic ammonia and restores cognitive function in patients with type 2 diabetes mellitus with varying degrees of liver damage.

References

Ali R, Nagalli S. Hyperammonemia, Treasure Island, 2021, available at: https://www.ncbi.nlm.nih.gov/books/NBK557504/

Upadhyay R, Bleck TP, Busl KM. Case Rep Med 2016;2016: 8512721.

Olde Damink SW, Jalan R, Dejong CH. Metab Brain Dis 2009;24(1): 169-181.

Tomson KL, et al. Medical Hypotheses 2018;113: 91-97. https://doi.org/10.1016/j.mehy.2018.02.010

Ageeva EA, Alekseenko SA. Gastrojenterologija 2017;16: 6-8.

Ong JP, Aggarwal A, Krieger D, et al. Am J Med 2003;114(3): 188-193.

Bueverov AO. Klin perspektivy gastrojenterologii, gepatologii 2012;6: 3-10.

Gunanithi K, Sakthi Dasan S, Sultan Sheriff D. IOSR J Dental Med Sci 2016;15(10): 14-19. https://doi.org/10.9790/0853-1510031419

Lu M, Bai J, Xu B, et al. Poult Sci 2017;96(1): 88-97. https://doi.org/10.3382/ps/pew285.

Santos CL, Bobermin LD, Souza DG, et al. Toxicol in Vitro 2015;29(7): 1350-1357. https://doi.org/10.1016/j.tiv.2015.05.023.

Zherdeva NN, Rozova EV, Man’kovskij BN. Medicina 2016;11: 65-72.

Rocamonde B, Paradells S, Barcia C, et al. Clin Dev Immunol 2013;2013: 521939.

Rocamonde B, Paradells S, Barcia JM, et al. Neuroscience 2012;224: 102-115.

Xia X, Su C, Fu J, et al. Int Immunopharmacol 2014;22: 293-302.

Bobermin LD, Souza DO, Goncalves CA, Quincozes-Santos A. Toxicol In Vitro 2013;27: 2041-2048.

Rangroo Thrane V, Thrane A, Wang F, et al. Nat Med 2013;19: 1643-1648. https://doi.org/10.1038/nm.3400.

Vilstrup H, Amodio P, Bajaj J, et al. Hepatology 2014;60: 715-735. https://doi.org/10.1002/hep.27210.

Downloads

Published

2022-03-15

How to Cite

Жердьова, Н., Степура, О., Іскандерова, Е., Мазій, С., Стрижак, Ю., & Хорєвіна, К. (2022). POSSIBILITIES OF CORRECTION OF HYPERAMMONEMIA IN THE PATIENTS WITH TYPE 2 DIABETES MELLITUS. Problems of Endocrine Pathology, 79(1), 112-117. https://doi.org/10.21856/j-PEP.2022.1.15

Issue

Section

TO PRACTICING ENDOCRINOLOGISTS

Most read articles by the same author(s)